CM
MBX

Capula Management’s MBX Biosciences MBX Stock Holding History

Capula Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,362
Closed -$217K – 632
2024
Q3 		$217K Buy
+8,362
New +$191K ﹤0.01% 363

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capula Management's MBX Position: Q4 2024 in Review

Capula Management sold out of MBX Biosciences (MBX) in Q4 2024, closing a stake of 8,362 shares — an estimated $217K sold.

Capula Management first reported a position in MBX in Q3 2024 and held it in 1 quarter. The position peaked at $217K in Q3 2024. 63 funds tracked by Wall St. Rank hold MBX as of Q4 2024.

  • Capula Management reported no remaining MBX Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capula Management sold 8,362 MBX Biosciences shares in Q4 2024, an estimated $217K.
  • Capula Management first reported a position in MBX Biosciences in Q3 2024 and held it in 1 quarter.
  • Capula Management's MBX Biosciences position peaked at $217K in Q3 2024.
  • 63 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2024.

Based on Capula Management's 13F filing for Q4 2024, filed 13 Feb 2025.